Download Drug Design and Discovery in Alzheimer’s Disease Ebook PDF

Drug Design and Discovery in Alzheimer’s Disease

Drug Design and Discovery in Alzheimer’s Disease
A Book

by Atta-ur-Rahman,Muhammad Iqbal Choudhary

  • Publisher : Elsevier
  • Release : 2015-06-27
  • Pages : 784
  • ISBN : 0128039604
  • Language : En, Es, Fr & De
GET BOOK

Drug Design and Discovery in Alzheimer’s Disease includes expert reviews of recent developments in Alzheimer's disease (AD) and neurodegenerative disease research. Originally published by Bentham as Frontiers in Drug Design and Discovery, Volume 6and now distributed by Elsevier, this compilation of the sixteen articles, written by leading global researchers, focuses on key developments in the understanding of the disease at molecular levels, identification and validation of molecular targets, as well as innovative approaches towards drug discovery, development, and delivery. Beginning with an overview of AD pharmacotherapy and existing blockbuster drugs, the reviews cover the potential of both natural and synthetic small molecules; the role of cholinesterases in the on-set and progression of AD and their inhibition; the role of beta-site APP clearing enzyme-1 (BACE-1) in the production of ß-amyloid proteins, one of the key reasons of the progression of AD; and other targets identified for AD drug discovery. Edited and written by leading experts in Alzheimer’s disease (AD) and other neurodegenerative disease drug development Describes existing drugs for AD and current molecular understanding of the condition Reviews recent advances in the field, including coverage of cholinesterases, BACE-1, and other drug development targets

Drug Design and Discovery in Alzheimer's Disease

Drug Design and Discovery in Alzheimer's Disease
A Book

by Atta-Ur-Rahman,Muhammad Iqbal Choudhary

  • Publisher : Bentham Science Publishers
  • Release : 2015-06-02
  • Pages : 784
  • ISBN : 9780128039595
  • Language : En, Es, Fr & De
GET BOOK

Drug Design and Discovery in Alzheimer's Disease includes expert reviews of recent developments in Alzheimer's disease (AD) and neurodegenerative disease research. Originally published by Bentham as Frontiers in Drug Design and Discovery, Volume 6and now distributed by Elsevier, this compilation of the sixteen articles, written by leading global researchers, focuses on key developments in the understanding of the disease at molecular levels, identification and validation of molecular targets, as well as innovative approaches towards drug discovery, development, and delivery. Beginning with an overview of AD pharmacotherapy and existing blockbuster drugs, the reviews cover the potential of both natural and synthetic small molecules; the role of cholinesterases in the on-set and progression of AD and their inhibition; the role of beta-site APP clearing enzyme-1 (BACE-1) in the production of ß-amyloid proteins, one of the key reasons of the progression of AD; and other targets identified for AD drug discovery. Edited and written by leading experts in Alzheimer's disease (AD) and other neurodegenerative disease drug development Describes existing drugs for AD and current molecular understanding of the condition Reviews recent advances in the field, including coverage of cholinesterases, BACE-1, and other drug development targets

Frontiers in CNS Drug Discovery

Frontiers in CNS Drug Discovery
A Book

by Atta-ur- Rahman,M. Iqbal Choudhary

  • Publisher : Bentham Science Publishers
  • Release : 2017-12-19
  • Pages : 264
  • ISBN : 1681084430
  • Language : En, Es, Fr & De
GET BOOK

Frontiers in CNS Drug Discovery is a book series devoted to publishing reviews which highlight the latest advances in drug design and discovery for disorders of the central nervous system (CNS). Eminent scientists write contributions on all areas of CNS drug design and drug discovery, including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The book series is essential reading for all pharmaceutical scientists involved in CNS drug design and discovery who wish to keep abreast of rapid and important developments in the field. The third volume of this series brings reviews on brain tumor treatment, neurodegeneration, hyperalgesia, cholinesterase inhibition and much more.

Structure-Based Drug Design for Diagnosis and Treatment of Neurological Diseases

Structure-Based Drug Design for Diagnosis and Treatment of Neurological Diseases

by Rona R. Ramsay,Giuseppe Di Giovanni

  • Publisher : Frontiers Media SA
  • Release : 2017-03-24
  • Pages : 129
  • ISBN : 2889451232
  • Language : En, Es, Fr & De
GET BOOK

European Cooperation in Science and Technology (COST) supports the collaboration of nationally-funded science and technology research through the creation of networks. COST is the longest-running European framework enhancing cooperation among researchers, engineers and scholars across Europe. The COST Action CM1103 “Structure-based drug design for diagnosis and treatment of neurological diseases: dissecting and modulating complex function in the monoaminergic systems of the brain” is a good example of the advances possible through interdisciplinary collaboration on difficult problems. COST Action CM1103 brought together 28 research groups from 18 countries to collaborate for four years on multi-target drug design for complex neuropathologies. The interdisciplinary expertise of the members is spans the range from computational enzymology to human studies, providing outstanding opportunities for the interdisciplinary development of trainees, and is reflected in the articles in this e-book. This Research Topic covers progress in multi-target drug design for the complex neuropathologies of the monoamine system that are apparent, for example, in Alzheimer’s disease. After a mini-review to introduce the topic of multi-target drug design, the other articles review the Research topic from their own perspective, two from computational approaches, three from medicinal chemistry, two from molecular pharmacology, and two from studies in whole brain. This multi-faceted approach describes new compounds, new methodology, and advances in the basic science of understanding the brain. This Ebook is based upon work from COST Action (CM1103 “Structure-based drug design for diagnosis and treatment of neurological diseases: dissecting and modulating complex function in the monoaminergic systems of the brain"), supported by COST (European Cooperation in Science and Technology). COST (European Cooperation in Science and Technology) is a pan-European intergovernmental framework. Its mission is to enable break-through scientific and technological developments leading to new concepts and products and thereby contribute to strengthening Europe’s research and innovation capacities. It allows researchers, engineers and scholars to jointly develop their own ideas and take new initiatives across all fields of science and technology, while promoting multi- and interdisciplinary approaches. COST aims at fostering a better integration of less research intensive countries to the knowledge hubs of the European Research Area. The COST Association, an International not-for-profit Association under Belgian Law, integrates all management, governing and administrative functions necessary for the operation of the framework. The COST Association has currently 36 Member Countries. www.cost.eu

Immune Dysfunctions

Immune Dysfunctions
New Targets of Drug Discovery for Alzheimer's Disease and Other Cognitive Disorders

by Michael Forster,Konrad C. Retz,Barry Reisberg

  • Publisher : Unknown Publisher
  • Release : 1988
  • Pages : 241
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders

Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders
Alzheimer's Disease

by Adeboye Adejare

  • Publisher : Academic Press
  • Release : 2016-09-20
  • Pages : 316
  • ISBN : 0128028114
  • Language : En, Es, Fr & De
GET BOOK

Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders: Alzheimer’s Disease examines the drug discovery process for neurodegenerative diseases by focusing specifically on Alzheimer’s Disease and illustrating the paradigm necessary to ensure future research and treatment success. The book explores diagnosis, epidemiology, drug discovery strategies, current therapeutics, and much more to provide a holistic approach to the discovery, development, and treatment of Alzheimer’s Disease. Through its coverage of the latest research in targeted drug design, preclinical studies, and mouse and rat models, the book is a must-have resource for all pharmaceutical scientists, pharmacologists, neuroscientists, and clinical researchers working in this area. It illustrates why these drugs tend to fail at the clinical stage, and examines Alzheimer’s Disease within the overall context of improving the drug discovery process for the treatment of other neurodegenerative disorders. Provides a compilation of chemical considerations required in drug discovery for the treatment of neurodegenerative disorders Examines different classes of compounds currently being used in discovery and development stages Explores in vitro and in vivo models with respect to their ability to translate these models to human conditions Distills the most significant information across multiple areas of Alzheimer’s disease research to provide a single, comprehensive, and balanced resource

Imaging in CNS Drug Discovery and Development

Imaging in CNS Drug Discovery and Development
Implications for Disease and Therapy

by David Borsook,Lino R. Beccera,Edward Bullmore,Richard J. Hargreaves

  • Publisher : Springer Science & Business Media
  • Release : 2010-03-10
  • Pages : 396
  • ISBN : 1441901345
  • Language : En, Es, Fr & De
GET BOOK

Drug development today needs to balance agility, speed, and risk in defining probability of success for molecules, mechanisms, and therapeutic concepts. New techniques such as fMRI promise to be part of a sequence that could transform drug development. Although numerous review articles exist that discuss the use of imaging in drug development, no one source is available that combines the various techniques and includes a discussion of disease mapping. Imaging in CNS Drug Discovery and Development, Implications for Disease and Therapy will serve to distill the most salient developments in the use of imaging in drug development and disease mapping. It will launch evolving concepts that integrate new imaging technologies and paradigms with molecular medicine and molecular profiling ("monics") as well as consider the ethical issues that arise as a result of disease or state diagnosis and the use of imaging in the public eye.

BACE

BACE
Lead Target for Orchestrated Therapy of Alzheimer's Disease

by Varghese John

  • Publisher : John Wiley & Sons
  • Release : 2010-03-15
  • Pages : 288
  • ISBN : 047029342X
  • Language : En, Es, Fr & De
GET BOOK

BACE inhibitors and their use in the treatment of Alzheimer's Disease BACE (β-site of APP cleaving enzyme) is a critical component in Alzheimer's Disease (AD), and the development of BACE inhibitors shows great potential as a therapy for the disease. BACE: Lead Target for Orchestrated Therapy of Alzheimer's Disease covers virtually all aspects of BACE from initial identification, discovery of inhibitors, and challenges in clinical development, while providing a global understanding essential for productive and successful drug discovery. This book details the story of the discovery of BACE and its role in AD and comprehensively discusses: The development of BACE inhibitors as therapeutics for Alzheimer's disease The research that led to the identification of BACE New BACE inhibitors currently being clinically tested ADME (absorption, distribution, metabolism, excretion) and clinical trial design—topics not addressed in current field literature Cutting-edge technology such as high-throughput screening, structure-based drug design, and QSAR in context of BACE inhibitors and Alzheimer's drug discovery Other approaches to BACE inhibition based on interaction with the precursor protein APP By enhancing the reader's understanding of the various aspects of the BACE drug-discovery process, this much-needed reference will serve as a key resource for all scientists involved in Alzheimer's research—and inspire new approaches to treatment of AD.

Drug Discovery and Development for Alzheimer's Disease, 2000

Drug Discovery and Development for Alzheimer's Disease, 2000
A Book

by Howard M. Fillit, MD,Alan W. O'Connell, PhD

  • Publisher : Springer Publishing Company
  • Release : 2002-01-03
  • Pages : 296
  • ISBN : 9780826115348
  • Language : En, Es, Fr & De
GET BOOK

This prestigious volume presents the findings of an international group of academic and biotechnological researchers. Topics range from early detection programs focusing on genetic factors, novel probes for detecting B-amyloid in the living brain, and the use of telephonic screening and MRI's to the diversity of therapeutic areas such as antioxidants, estrogen agonists and various anti-B-amyloid and anti-tangle approaches. The volume is still an indispensable resource for the psychogeriatrician, psychiatrist, clinical investigator, and neurobiologist, and a must for medical libraries.

Attrition in the Pharmaceutical Industry

Attrition in the Pharmaceutical Industry
Reasons, Implications, and Pathways Forward

by Alex,Alexander Alex,C. John Harris,Dennis A. Smith

  • Publisher : John Wiley & Sons
  • Release : 2015-12-29
  • Pages : 384
  • ISBN : 1118679679
  • Language : En, Es, Fr & De
GET BOOK

With a focus on case studies of R&D programs in a variety of disease areas, the book highlights fundamental productivity issues the pharmaceutical industry has been facing and explores potential ways of improving research effectiveness and efficiency. Takes a comprehensive and holistic approach to the problems and potential solutions to drug compound attrition Tackles a problem that adds billions of dollars to drug development programs and health care costs Guides discovery and development scientists through R&D stages, teaching requirements and reasons why drugs can fail Discusses potential ways forward utilizing new approaches and opportunities to reduce attrition

Treating Alzheimer's Disease

Treating Alzheimer's Disease
New Directions in Drug Discovery and Development : Special Issue

by Howard Fillit,Lorenzo M. Refolo

  • Publisher : Unknown Publisher
  • Release : 2004
  • Pages : 172
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

Design of Hybrid Molecules for Drug Development

Design of Hybrid Molecules for Drug Development
A Book

by Michael Decker

  • Publisher : Elsevier
  • Release : 2017-04-05
  • Pages : 352
  • ISBN : 0081011180
  • Language : En, Es, Fr & De
GET BOOK

Design of Hybrid Molecules for Drug Development reviews the principles, advantages, and limitations involved with designing these groundbreaking compounds. Beginning with an introduction to hybrid molecule design and background as to their need, the book goes on to explore a range of important hybrids, with hybrids containing natural products, molecules containing NO- and H2S-donors, dual-acting compounds acting as receptor ligands and enzyme inhibitors, and the design of photoresponsive drugs all discussed. Drawing on practical case studies, the hybridization of molecules for development as treatments for a number of key diseases is then outlined, including the design of hybrids for Alzheimer's, cancer, and malaria. With its cutting-edge reviews of breaking developments in this exciting field, the book offers a novel approach for all those working in the design, development, and administration of drugs for a range of debilitating disorders. Highlights an approach unimpaired by the limitations of the classical search for lead structures - one of the core problems in modern drug development processes, making the content of high relevance for both academic and non-academic drug development processes Pulls together research and design techniques in a novel way to give researchers the best possible platform from which to review the approaches and techniques applied Compares the advantages and disadvantages of these compounds Includes the very latest developments, such as photoactivatable and photo-responsive drugs

Frontiers in CNS Drug Discovery

Frontiers in CNS Drug Discovery
A Book

by Atta-ur-Rahman,M. Iqbal Choudhary

  • Publisher : Bentham Science Publishers
  • Release : 2013-09-10
  • Pages : 415
  • ISBN : 1608057674
  • Language : En, Es, Fr & De
GET BOOK

“Frontiers in CNS Drug Discovery” is an eBook series devoted to publishing the latest and the most important advances in Central Nervous System (CNS) drug design and discovery. Eminent scientists write contributions on all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The eBook series should prove to be of interest to all pharmaceutical scientists involved in research in CNS drug design and discovery. Each volume is devoted to the major advances in CNS drug design and discovery. The eBook series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field.

Frontiers in CNS Drug Discovery

Frontiers in CNS Drug Discovery
A Book

by Atta-ur Rahman,M. Iqbal Choudhary

  • Publisher : Bentham Science Publishers
  • Release : 2011-08-12
  • Pages : 653
  • ISBN : 1608051595
  • Language : En, Es, Fr & De
GET BOOK

"Frontiers in CNS Drug Discovery" is an Ebook series devoted to publishing the latest and the most important advances in Central Nervous System (CNS) drug design and discovery. Eminent scientists write contributions on all areas of rational drug design an

Molecular Insight of Drug Design

Molecular Insight of Drug Design
A Book

by Arli Aditya Parikesit

  • Publisher : BoD – Books on Demand
  • Release : 2018-08-29
  • Pages : 130
  • ISBN : 1789236320
  • Language : En, Es, Fr & De
GET BOOK

The approaches in drug design are mainly comprised of these three multidisciplinary sciences. First, Bioinformatics has successfully gather biological data in form of biomolecular sequences, in order to construct knowledge on drug and vaccine design. It is of considerable importance for drug designers to comprehend the utilization of bioinformatics tools for resolving their research questions. Second, Nanotechnology has made possible the design and delivery of the nano-based drug. Third, Pharmaceutical Chemistry made it possible to investigate the adsorption, distribution, metabolism, and toxicology of the drug candidates in a fine-grained resolution.

Immune Dysfunctions

Immune Dysfunctions
New Targets for Drug Discovery for Alzheimer's Disease and Other Cognitive Disorders : Symposium on Autoimmunity: Its Role in Alzheimers Disease and Other Behavioral Functions : 17th Annual Meeting : Papers

by Anonim

  • Publisher : Unknown Publisher
  • Release : 1988
  • Pages : 129
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

Translating Molecules into Medicines

Translating Molecules into Medicines
Cross-Functional Integration at the Drug Discovery-Development Interface

by Shobha N. Bhattachar,John S. Morrison,Daniel R. Mudra,David M. Bender

  • Publisher : Springer
  • Release : 2017-04-21
  • Pages : 461
  • ISBN : 3319500422
  • Language : En, Es, Fr & De
GET BOOK

Tackling translational medicine with a focus on the drug discovery development-interface, this book integrates approaches and tactics from multiple disciplines, rather than just the pharmaceutical aspect of the field. The authors of each chapter address the paradox between the molecular understanding of diseases, drug discovery, and drug development. Laying out the detailed trends from various fields, different chapters are dedicated to target engagement, toxicological safety assessments, and the compelling relationship of optimizing early clinical studies with design strategies. The book also highlights the importance of balancing the three pillars: sufficient efficacy, acceptable safety and appropriate pharmacokinetics, all of which are crucial to successful efforts in discovery and development. With discussions regarding the combined approaches of molecular research, personalized medicine, pre-clinical and clinical development, as well as targeted therapies—this compendium is a flexible fit, perfect for professionals in the pharmaceutical industry and related academic fields.

Drug Discovery Strategies and Methods

Drug Discovery Strategies and Methods
A Book

by Alexandros Makriyannis,Diane Biegel

  • Publisher : CRC Press
  • Release : 2003-11-04
  • Pages : 348
  • ISBN : 082475767X
  • Language : En, Es, Fr & De
GET BOOK

Navigate the complex and multidisciplinary path of drug discovery procedures with Drug Discovery Strategies and Methods-a well-organized and timely reference that analyzes methods in target identification and validation, lead detection, compound optimization, and biological testing. This volume addresses challenges encountered during the discovery of new pharmaceutical candidates including the use of cutting-edge techniques utilized in drug design and development. It considers key elements in the drug design cycle ranging from appropriateness of targets and disease models to compound characterization, safety, and efficacy and the role of protein crystallography in structure-based drug design.

Computational Approaches for Identifying Drugs Against Alzheimer's Disease

Computational Approaches for Identifying Drugs Against Alzheimer's Disease
A Book

by Radha Mahendran,Suganya Jeyabaskar,Astral Gabriella Francis

  • Publisher : Anchor Academic Publishing
  • Release : 2017-05
  • Pages : 72
  • ISBN : 3960671385
  • Language : En, Es, Fr & De
GET BOOK

Alzheimer’s disease is the most common form of dementia which is incurable. Although some kinds of memory loss are normal during aging, these are not severe enough to interfere with the level of function. ß-Secretase is an important protease in the pathogenesis of Alzheimer’s disease. Some statine-based peptidomimetics show inhibitory activities to the ß-secretase. To explore the inhibitory mechanism, molecular docking and three-dimensional quantitative structure-activity relationship (3D-QSAR) studies on these analogues were performed. Quantitative structure-activity relationship (QSAR) modeling pertains to the construction of predictive models of biological activities as a function of structural and molecular information of a compound library. The concept of QSAR has typically been used for drug discovery and development and has gained wide applicability for correlating molecular information with not only biological activities but also with other physicochemical properties, which has therefore been termed quantitative structure-property relationship (QSPR). In this study, 3D QSAR and pharmacophore mapping studies were carried out using Accelrys Discovery Studio 2.1. The best nine drugs were selected from the 16 ligands and pharmacophore features were generated.

Emerging Drugs and Targets for Alzheimer's Disease: Beta-amyloid, tau protein and glucose metabolism

Emerging Drugs and Targets for Alzheimer's Disease: Beta-amyloid, tau protein and glucose metabolism
A Book

by Ana Martínez

  • Publisher : Royal Society of Chemistry
  • Release : 2010
  • Pages : 317
  • ISBN : 1849730636
  • Language : En, Es, Fr & De
GET BOOK

This volume describes the discovery and development history of the most promising drugs now in development for combating Alzheimer's disease.